Effects of peripheral administration of 5-hydroxytryptamine (5-HT) on 2-deoxy-D-glucose-induced hyperphagia in rats

Biological and Pharmaceutical Bulletin

Volumn 25, Issue 10, 2002, Pages 1364-1366

  Sugimoto, Yumi ^a   Yoshikawa, Tomoko ^a   Yamada, Jun ^a  

^a KOBE PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

2 deoxy D glucose; 5 HT (5 hydroxytryptamine, serotonin); Food intake; Glucoprivation; Peripheral 5 HT2A receptor

Indexed keywords

DEOXYGLUCOSE; KETANSERIN; SEROTONIN; SEROTONIN 2A ANTAGONIST; SEROTONIN 2A RECEPTOR; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; FEEDING; HYPERGLYCEMIA; HYPERPHAGIA; MALE; NONHUMAN; RAT; ANIMAL; BLOOD; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; DRUG EFFECT; EATING; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; DEOXYGLUCOSE; EATING; HYPERPHAGIA; MALE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, SEROTONIN; SEROTONIN; SEROTONIN ANTAGONISTS;

EID: 0036780531     PISSN: 09186158     EISSN: None     Source Type: Journal    
DOI: 10.1248/bpb.25.1364     Document Type: Article

References (22)

1. Blundell J. E., Neuropharmacology, 23, 1537-1551 (1984).
2. Curzon G., Ann. N.Y. Acad. Sci. 600, 521-531 (1990).
3. Dourish C. T., Obesity Res., 3, 449S-462S (1995).
4. Dourish C. T., Houtoson P. H., Curzon G., Psychopharmnacology, 89, 467-471 (1986).
5. Kennen G. A., Dourish C. T., Curzon G., Eur. J. Pharmacol., 141, 429-435 (1987).
6. Kennett G. A., Curzon G., Brit. J. Pharmacol., 103, 2016-2020 (1991).
7. Kennett G. A., Curr. Opin. Invest. Drugs. 2, 317-362 (1992).
8. Edwards S., Stevens R. G., Pharmacol. Biochem. Behav., 34, 717-720 (1989).
9. Francis J. D., Critchley D. J. P., Dourish C. T., Cooper S. J., Pharmacol. Biochem. Behav., 50, 581-585 (1995).
10. Pollock J. D., Rowland N., Pharmacol. Biochem. Behav., 15, 179-183 (1981).
11. Sugimoto Y., Yamada J., Yoshikawa T., Noma T., Horisaka K., Eur. J. Pharmacol., 316, 15-21 (1996).
12. Smith G. P., Epstein A. N., Am. J. Physiol., 217, 1083-1087 (1969).
13. Berthoud H. R., Mogenson G. J., Am. J. Physiol., 233, 127-133 (1977).
14. Chaouloff F., Laude D., Baudrie V., Eur. J. Pharmacol., 187, 435-443 (1990).
15. Sugimoto Y., Yamada J., Yoshikawa T., Horisaka K., Biol. Pharm. Bull., 19, 1384-1386 (1996).
16. Yamada J., Sugimoto Y., Yoshikawa T., Kimura I., Horisaka K., Life Sci., 57, 819-825 (1995).
17. Yamada J., Sugimoto Y., Noma T., Yoshikawa T., Eur. J. Pharmacol., 359, 81-86 (1998).
18. Sugimoto Y., Yamada J., Kimura I., Watanabe Y., Horisaka K., Jpn. J. Pharmacol., 60, 145-148 (1992).
19. Shimizu H., Bray G. A., Physiol. Behav., 46, 799-807 (1987).
20. Pascoe W. S., Smythe G. A., Storlien L. H., Brain Res., 505, 23-28 (1989).
21. Baker B. J., Duggan J. P., Barber D. J., Booth D. A., Eur. J. Pharmacol., 150, 137-142 (1988).
22. Eberle-Wang K., Braun B. T., Simansky K. J., Am. J. Physiol., 266, R284-R291 (1994).